You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Our collaboration and licensing arrangements, as well as any future collaboration and licensing arrangements that we may enter into, may not be successful. The success of our collaboration and licensing arrangements will depend heavily on the efforts and activities of our collaborators, which are not within our control. We may, in the course of our collaboration and licensing arrangements, be subject to numerous risks, including, but not limited to, the following: our collaborators may have significant discretion in determining the efforts and resources that they will contribute; | our collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing. For example, in July 2018, GSK notified us of its decision to discontinue development of the inhaled antiviral for viral exacerbations in COPD, part of the GSK ICO Agreement, after completion of its related Phase 1 clinical trial and we do not believe that GSK is currently advancing any program under our collaboration; | our collaborators may independently, or in conjunction with others, develop products that compete directly or indirectly with our product candidates; | we may grant exclusive rights to our collaborators that would restrict us from collaborating with others. For example, we are currently subject to certain restrictions with regard Assistant:
- Assistant
Positive: Our partnerships and licensing deals, along with any future agreements we might pursue, may not turn out favorably. The outcome of these collaborations and licensing contracts will largely rely on the dedication and actions of our partners, which are beyond our control. Throughout these endeavors, we could encounter various risks, including but not limited to: our partners might have considerable leeway in deciding the efforts and resources they will allocate; | our partners may postpone clinical trials, underfund a clinical trial initiative, halt a clinical trial, abandon a product candidate, redo or initiate new clinical trials or demand a new formulation of a product candidate for clinical evaluation. For instance, in July 2018, GSK informed us of its choice to cease development of the inhaled antiviral for viral exacerbations in COPD, which was part of the GSK ICO Agreement, following the completion of a Phase 1 clinical test, and we don’t think GSK is currently advancing any programs within our partnership; | our partners may, on their own or with others, create products that directly or indirectly compete with our product candidates; | we might provide exclusive rights to our partners that would limit our ability to collaborate with others. For instance, we're presently bound by specific restrictions in this regard.
Negative: Our collaboration and licensing arrangements, as well as any future partnerships we may engage in, will undoubtedly be successful. The triumph of our collaboration and licensing agreements will be predominantly influenced by our own efforts and activities, which are entirely under our control. We will not face any risks during our collaboration and licensing processes; our collaborators will have minimal discretion in determining the contributions of their efforts and resources; | our collaborators will accelerate clinical trials, ensure adequate funding for the clinical trial program, continue clinical trials, maintain product candidates, and avoid repeating or conducting new clinical trials or requiring a new formulation of a product candidate for testing. For instance, in July 2018, GSK assured us of its commitment to continue developing the inhaled antiviral for viral exacerbations in COPD, part of the GSK ICO Agreement, following the successes of its Phase 1 clinical trial, and we strongly believe GSK is advancing further with all programs under our collaboration; | our collaborators will not develop any competing products independently; | we will never grant exclusive rights to our collaborators that would restrict us from partnering with others. For example, we are not subject to any collaboration restrictions currently.